Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Rx Importation Will Have Its Day In Court: Vermont Plans Lawsuit Against FDA

This article was originally published in The Pink Sheet Daily

Executive Summary

Agency’s denial of Vermont’s petition to set up a “responsible” drug reimportation program leaves “no alternative” but to sue, the state says.

You may also be interested in...



Canada To Block U.S. Drug Importation With Legislative, Regulatory Actions

Health Canada plans to require an established physician-patient relationship before a U.S. prescription could be filled in a Canadian pharmacy. Health ministry will also introduce legislation prohibiting bulk exports to the U.S. Steps are pre-emptive strike against actions by states and legislation pending in Congress.

Canada To Block U.S. Drug Importation With Legislative, Regulatory Actions

Health Canada plans to require an established physician-patient relationship before a U.S. prescription could be filled in a Canadian pharmacy. Health ministry will also introduce legislation prohibiting bulk exports to the U.S. Steps are pre-emptive strike against actions by states and legislation pending in Congress.

FDA Wants Broad Reimportation Enforcement Discretion

The agency may seek an accelerated ruling in Vermont's lawsuit against FDA in light of decisions by other states to implement importation programs. FDA Acting Commissioner Crawford tells a conference in Geneva, Switzerland that a decision on imports should be left to the agency.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS060271

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel